Rallybio
RLYB
Rallybio (RLYB) news
Recent news
Rallybio - Athena Countouritis to lead combined company as chair, president and CEO
AInvest Wire · Jun 1, 2026Rallybio - pre-deal Rallybio equityholders to own 2.8%, Avenzo equityholders 97.2% of combined company
AInvest Wire · Jun 1, 2026Rallybio, Avenzo Therapeutics report merger pact
Rallybio Corporation (NASDAQ: RLYB) has announced the termination of its previously disclosed merger agreement with Candid Therapeutics Inc., a San Diego-based biotechnology company. The merger, which was initially announced in March 2026, would have combined the two companies under the Candid…
AInvest Wire · Jun 1, 2026Rallybio - combined company to operate as Avenzo Therapeutics, trade as AVZO on Nasdaq
AInvest Wire · Jun 1, 2026ImportantRallybio shares rise 60% premarket on investment from J&J, collaboration
AInvest Wire · Apr 11, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.